European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...

LONDON, UK I July 24, 2025 I GSK plc (LSE/NYSE: GSK) today announced the approval of Blenrep in the European Union (EU) for the treatment of adults with ...

(Alliance News) - GSK PLC on Thursday said its Blenrep blood cancer treatment has been approved in Europe, as it awaits a final decision from the US regulator. The London-based pharmaceutical firm ...

US FDA extends the review period for GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Friday, July 25, 2025, 11:00 Hrs [IST] GSK plc announce ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday.

FDA extends Blenrep combo review to October to assess more data from Phase 3 trials in relapsed or refractory multiple myeloma.

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

GSK plc (LSE/NYSE: GSK) announced its sponsorship of the 2025 National Senior Games as part of its nationwide Sideline RSV campaign, a health education campaign aimed at helping educate older adults ...

London: GSK plc has announced the extension of the US Food and Drug Administration (FDA) review period for the Biologics ...